transplant outcome. However, it was developed using data for only 61 patients in an era of limited therapy for GVHD prevention. It is unknown whether the Glucksberg groupings of organ involvement are the most predictive in the modern era of allogeneic transplantation. There may also be considerable inter-observer variability in assigning Glucksberg grade, since it includes subjective assessment of performance (Glucksberg et al, 1974; Thomas et al, 1975) .
We analysed the association between Glucksberg grade of acute GVHD and outcome in 2129 adult recipients of non-Tcell-depleted HLA-identical sibling transplants for leukaemia with cyclosporine (CSA) and methotrexate (MTX) for GVHD prophylaxis. Transplants were carried out between 1986 and 1992. Higher Glucksberg grade predicted poorer transplant outcome. However, patients with the same grade but with different patterns of skin, liver and gut involvement often had significantly different risks of treatment-related mortality (TRM) and treatment failure (relapse or death). We constructed a Severity Index, rating acute GVHD from A to D on the basis of organ involvement alone, grouping patients with similar risks of outcome. The prognostic utility of this Severity Index was confirmed in an independent data set of 752 patients receiving T-celldepleted transplants.
METHODS

Patients.
The study included patients у16 years of age surviving у 21 d with engraftment after a single HLAidentical sibling bone marrow transplant for acute myelogenous (AML), acute lymphoblastic (ALL) or chronic myelogenous leukaemia (CML) using post-transplant CSA and MTX or T-cell depletion with or without post-transplant immune suppression to prevent acute GVHD. Transplants were performed between 1 January 1986 and 31 December 1992 and reported to the International Bone Marrow Transplant Registry (IBMTR) by 161 transplant centres. The IBMTR had data on 2945 eligible patients; 64 were excluded because of incomplete data for skin, liver or gut involvement or for date of onset of acute GVHD. 2881 patients were studied. 2129 patients receiving non-T-celldepleted transplants were used to determine the association between Glucksberg grade and outcome and to develop a revised Index of acute GVHD severity. The prognostic utility of the Severity Index was studied in 752 patients receiving T-cell-depleted transplants.
Staging of skin, liver and gut involvement and Glucksberg grade. Reporting teams were instructed to use the criteria of Thomas (Thomas et al, 1975) to assign a stage of maximum severity of skin, liver and gut involvement with acute GVHD (Table I) . We used the reported organ stages to assign Glucksberg grades (Thomas et al, 1975) (Table I) . Because of the subjective nature of differentiating a 'marked' from an 'extreme' decrease in clinical performance, which is the only criterion differentiating Grades III and IV, our analysis considered Grades III and IV as a single category.
The reported organ stage is the maximum stage of involvement for the patient's episode of acute GVHD regardless of treatment response. The time to onset indicates time from transplant to first evidence of acute GVHD.
Endpoints. Study endpoints were time to relapse, TRM, and treatment failure. TRM was defined as death in patients without relapse, with censoring at time of relapse or last follow-up. Treatment failure was defined as death or relapse with patients alive and free of disease censored at time of last follow-up.
Statistical methods. Relative risks (RR) of transplant outcomes were determined using Cox proportional hazards regression (Cox et al, 1972) . Patients without acute GVHD were the reference group for all calculations of RR. Acute GVHD entered the model as a time-dependent variable so that prior to onset the patient was considered in the reference group. Because age and disease state at transplant are major prognostic factors for transplant outcome (Thomas et al, 1986; Clift et al, 1987; Barrett et al, 1989; Rowlings et al, 1995) , all analyses were stratified on these covariates. Patients were considered in age groups 16-30 or >30 years and in early (first remission acute leukaemia and first chronic phase CML), intermediate (second or later remission of acute leukaemia and second chronic or accelerated phase CML) and advanced (acute leukaemia not in remission and CML in blast phase) disease states. RRs of relapse, TRM and treatment failure were calculated separately for patients with Glucksberg Grade I, Grade II and Grade III/IV acute GVHD versus patients without acute GVHD. Differences in risk between patients with different grades were made using the Wald Chi-square test (Andersen et al, 1993) .
Severity Index. The association between unique patterns of organ involvement and outcome was examined. Preliminary analyses indicated no difference in prognostic significance of liver versus gut involvement and maximum stage in either of these two organs was used as an indicator of visceral acute GVHD. There are many potential combinations or patterns of skin (stages 0-4) and visceral (stages 0-4) involvement. Glucksberg Grade I acute GVHD includes two potential patterns: stage 1 skin without visceral involvement and stage 2 skin without visceral involvement. Glucksberg Grade II acute GVHD includes 13 potential patterns. Grades III/IV acute GVHD includes 109 potential patterns of organ involvement. RRs of TRM and treatment failure were compared between groups with distinct patterns of organ involvement. Differences in RR of TRM at a significance level of 0·05 were considered significant and those patterns were not combined. On the basis of these comparisons, we constructed a Severity Index grouping patients with acute GVHD into four risk categories, A-D.
The association between Severity Index and transplant outcome was then tested in 752 patients receiving T-celldepleted HLA-identical sibling transplants. The relationship between Severity Index and treatment failure was compared for the two groups (patients receiving T-cell-depleted or non T-cell-depleted grafts) by fitting the Severity Index model to each group seperately and then the combined population. The test of difference was computed by a likelihood ratio test (Andersen et al, 1993) .
International Bone Marrow Transplant Registry. The
International Bone Marrow Transplant Registry is a voluntary working group of over 250 transplant teams worldwide that contribute detailed data on their allogeneic bone marrow transplants to the Statistical Center at the Medical College of Wisconsin (Rimm et al, 1991; Horowitz & Bortin, 1992) . Participating teams must report all consecutive transplants; compliance is monitored by on-site audits. The IBMTR database includes 40-45% of all allogeneic transplant recipients since 1970. Patients are followed longitudinally. Computerized error checks, physician review of submitted data and on-site audits of participating centres ensure data quality.
RESULTS
Patients
Patient characteristics and incidences of Glucksberg grades of acute GVHD are shown in Table II . The incidence of Grade II-IV acute GVHD was 35% after non-T-cell-depleted and 28% after T-cell-depleted transplants.
Association between Glucksberg grade and outcome
RRs (compared to patients without acute GVHD) of relapse, TRM and treatment failure by Glucksberg grade are shown in Table III . Relapse risk was significantly lower in patients with, versus those without, acute GVHD (RR 0·74, P ¼ 0 : 004); however, among patients with acute GVHD there was little difference in relapse risk by grade. Patients with Glucksberg Grade I acute GVHD had similar risks of TRM and treatment failure as those without acute GVHD. Patients with Grades II and III/IV acute GVHD had incrementally higher risks of TRM and treatment failure. Table IV shows TRM and treatment failure for patients with distinct patterns of organ involvement within each Glucksberg grade. We identified two or more groups within each Glucksberg category with significantly different risks of TRM and treatment failure. Among patients with Glucksberg Grade I acute GVHD, patients with stage 1 skin involvement had significantly lower RR of TRM and treatment failure than those with stage 2 skin involvement (RR 0·84 v 1·83 Table I . Glucksberg clinical stage and grade of acute GVHD (Glucksberg et al, 1974; Thomas et al, 1975 (Table IV) . Table V shows RR of TRM and treatment failure associated with the patterns of organ involvement in Table IV , ordered by increasing risk of TRM. Using a difference in TRM with a significance level of 0·05 to distinguish groups, we created a revised Severity Index assigning patients with similar outcome into four groups, A-D (Table VI) . Group A includes patients with stage 1 skin acute GVHD only; B includes those with stage 2 skin and no visceral acute GVHD or stage 0-2 skin with stage 1 or 2 visceral acute GVHD; C includes patients with stage 3 skin, liver and/or gut acute GVHD; D Abbreviations: GVHD, graft-versus-host disease; CSA cyclosporine; MTX, methotrexate; TRM, treatment-related mortality.
Association between patterns of organ involvement and outcome
IBMTR Severity Index
*P indicates differences between adjacent rows.
includes those with stage 4 skin, liver and/or gut acute GVHD. Table VII shows RRs of relapse, TRM and treatment failure for patients in groups defined by the revised Severity Index.
Patients with an acute GVHD Index of A have similar risks of TRM and treatment failure as patients without acute GVHD. Those with Indices B-D have incrementally higher risks. 5 . 69 (4 . 57, 7 . 08) 5 . 47 (3 . 69, 8 . 11) Abbreviations: MTX, methotrexate; CSA, cyclosporine; GVHD, graft-versus-host disease. *P-value indicates differences between adjacent rows.
Figs 1 and 2 show probabilities of TRM and leukaemia-free survival for patients transplanted for early (first remission or first chronic phase) leukaemia by IBMTR Severity Index. Table VIII shows RR of treatment failure by IBMTR Severity Index in the original 2129 study patients (those receiving non-T-cell-depleted transplants with posttransplant CSA and MTX) and an independent data set of 752 recipients of T-cell-depleted transplants. The relationship between Severity Index and treatment failure was the same in both groups (test of difference rejected at P ¼ 0·89).
DISCUSSION
We studied more than 2000 patients receiving a single, commonly used, GVHD prophylaxis regimen to examine the relationship between grading systems and transplant outcome. Incidence of acute GVHD in these patients was similar to that reported by many centres including those not participating in the IBMTR (Nash et al, 1992) . We constructed a revised Severity Index with a strong association with transplant outcome.
The concept of modifying the Glucksberg grading system for acute GVHD is not new (Martin et al, 1990; Weisdorf et al, 1990; Vogelsang, 1990) and was addressed at a consensus conference in 1994 (Przepiorka et al, 1995) . Contributors to the consensus conference included the largest allogeneic transplant centres in North America and Europe, the European Group for Blood and Marrow Transplantation (EBMT) and the IBMTR. The conference concluded that although Glucksberg's system distinguished patients with different risks of outcome, as demonstrated in this study and a recent publication from the EBMT (Gratwohl et al, 1995) , additional studies were needed to evaluate possible diversity of outcome within GVHD grades, as was done in the current study (Przepiorka et al, 1995) . Previous modifications to Glucksberg's grading system were based on data from relatively few patients given various therapies to prevent acute GVHD.
We found that although the risks of TRM and treatment failure generally increased with increasing Glucksberg grade, patients with the same grade but different patterns of organ involvement often had significantly different risks of outcome. We also found similarities in outcome of patients with different Glucksberg grades (Table V) . For example, patients with stage 1 gut or liver involvement are classified as Glucksberg Grade II without regard to extent of skin involvement less than stage 4. However, we found that risk of treatment failure in these patients correlated with extent of skin involvement. Those with stage 0-2 skin acute GVHD had a RR of treatment failure of 1·11 whereas those with stage 3 skin involvement have a RR of 1·95 (P < 0·0001). Conversely, patients with stage 2 skin acute GVHD without gut and liver involvement (Glucksberg Grade I) and those with skin stage р 2 and gut and/or liver stage 2 (Glucksberg Grade III/IV) had similar risks of treatment failure, RR 1·17 v 1·43 (P ¼ 0·24). Furthermore, among patients with Glucksberg Grade III/IV acute GVHD, patients with increasing levels of severity of organ involvement had highly significant and clinically important differences in outcome.
To provide an Index with less heterogeneity, we reclassified the patterns of organ involvement based on transplant outcome (Table VI) . Unlike the Glucksberg grading system which differentiates grades in part by subjective assessment of performance status, the revised Severity Index is based solely on objective measurements of organ involvement. A group of patients receiving T-cell-depleted transplants was used to determine whether the Severity Index would predict outcome in an independent data set. In these patients, the RR of treatment failure by Index was similar. Evaluation of the Index's prognostic utility in children and in recipients of peripheral blood allografts is planned.
The outcome-based reclassification of patterns of organ involvement into groups may make this Severity Index more sensitive and specific for studying acute GVHD after allogeneic transplants. However, this Index must be tested prospectively. Such a study was begun by the French Society for Bone Marrow Transplant (SFGM) in January 1996. The SFGM study prospectively compares Glucksberg Grade and IBMTR Severity Index for their abilities to predict transplant outcome and response to treatment. The present analysis and the SFGM study will provide important data for design of future studies of acute GVHD and its effect on transplant outcome.
